Recreational Substance Use Linked to Premature Atherosclerotic CVD
Independent associations seen for use of tobacco, alcohol, cocaine, amphetamine, cannabis, other drugs, with stronger links for women
Addiction/dependence
Should Relaxed Methadone Rules Continue After the Pandemic Ends?
The authors propose evaluating which aspects of previous policy and practices for OUD should resume and which aspects of current policy and practice exemptions should continue.
Bupropion-Naltrexone Bests Placebo in Methamphetamine Use Disorder
Response was low but higher with naltrexone-bupropion than placebo during 12-week, two-stage trial
FDA Cracks Down on Websites Illegally Selling Opioids
The unapproved and misbranded opioids, which include tramadol and oxycodone, are being sold without a prescription.
About Half of Waivered Clinicians Prescribe Buprenorphine for OUD
Percentages much higher for actively prescribing U.S. clinicians with 275 and 100 versus 30 patients
MPR Weekly Dose Podcast Episode 48
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
Cannabidiol Studied as Potential Treatment for Cannabis Use Disorder
Abstinence from cannabis increased with cannabidiol 400mg, 800mg doses compared with placebo.
FDA Requires Labeling Changes for Opioids to Include Information About Naloxone
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
USPSTF Urges Primary Care Docs to Ask Adults About Drug Use
Evidence inadequate to assess benefits and harms of screening for unhealthy drug use in teens.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
